@moatrx
• 3 weeks ago
• comments: 0
Posted a new blog:
US COLD AGGLUTININ DISEASE Competitive Intelligence
US COLD AGGLUTININ DISEASE Competitive Intelligence
Sutimlimab is the only approved CAD therapy, yet 54% of patients met the composite hemoglobin-response endpoint against off-label rituximab.
Cold agglutinin...
@moatrx
• 3 weeks ago
• comments: 0
Posted a new blog:
US HR+/HER2- BREAST CANCER Competitive Intelligence
US HR+/HER2- BREAST CANCER Competitive Intelligence
Ribociclib is the only CDK4/6 inhibitor with a significant survival edge: 63.9 versus 51.4 months, while palbociclib's OS gain never reached significance.
The...
@moatrx
• 3 weeks ago
• comments: 0
Posted a new blog:
GCC ATTR AMYLOIDOSIS Competitive Intelligence
GCC ATTR AMYLOIDOSIS Competitive Intelligence
Tafamidis is SFDA-registered at an 80-90% tender discount, but fewer than 8 GCC centres can diagnose ATTR-CM.
Tafamidis (Vyndaqel/Vyndamax), which produced a 29.5%...
@moatrx
• 3 weeks ago
• comments: 0
Posted a new blog:
US ATOPIC DERMATITIS Competitive Intelligence
US ATOPIC DERMATITIS Competitive Intelligence
Dupilumab holds 70% biologic share in a $5B US market, but FDA black-box warnings push JAK inhibitors into second-line step-edits.
Six agents are approved for...
@moatrx
• 3 weeks ago
• comments: 0
Posted a new blog:
US ALZHEIMER'S DISEASE — Competitive Intelligence
US ALZHEIMER'S DISEASE — Competitive Intelligence
Lecanemab slows cognitive decline 27%, donanemab 35%, yet CMS amyloid confirmation and ARIA monitoring gate access for 6.7 million eligible US patients.
Two...
@moatrx
• 3 weeks ago
• comments: 0
Posted a new blog:
ATTR AMYLOIDOSIS — UK
ATTR AMYLOIDOSIS — UK
NICE's TA1121 verdict tells clinicians to pick whichever ATTR-CM stabiliser, tafamidis or acoramidis, costs less.
Transthyretin amyloidosis (ATTR) is two...
